• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Miromatrix Medical Inc.

    2/16/22 4:05:13 PM ET
    $MIRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MIRO alert in real time by email
    SC 13G 1 miromatrix_13g.htm SC 13G
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.    )*
     
    Miromatrix Medical Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.00001 per share
    (Title of Class of Securities)
     
    60471P108
    (CUSIP Number)
     
    February 11, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)
       

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).  

     
     
    CUSIP No. 60471P108 13G Page 2 of 8

     

                 
    1.

    Names Of Reporting Persons

    I.R.S. Identification No. Of Above Persons (Entities Only)

     

    GAGNON SECURITIES LLC

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    DELAWARE LIMITED LIABILITY COMPANY

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power     0
    6. shared voting power     650,444
    7. sole dispositive power     0
    8. shared dispositive power     684,984
    9. aggregate amount beneficially owned by each reporting person   684,984
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    3.4%

    12. type of reporting person (See Instructions)     IA, BD

     

     
     
     
    CUSIP No. 60471P108 13G Page 3 of 8

     

                 
    1.

    Names Of Reporting Persons

     

    GAGNON ADVISORS, LLC

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    DELAWARE LIMITED LIABILITY COMPANY

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power     0
    6. shared voting power     229,802
    7. sole dispositive power     0
    8. shared dispositive power    

    229,802

    9. aggregate amount beneficially owned by each reporting person  

    229,802

    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    1.1%

    12. type of reporting person (See Instructions)     IA

     

     
     
     
    CUSIP No. 60471P108 13G Page 4 of 8

     

                 
    1.

    Names Of Reporting Persons

     

    NEIL GAGNON

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    USA

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power    

    65,711

    6. shared voting power    

    915,651

    7. sole dispositive power    

    65,711

    8. shared dispositive power    

    952,753

    9. aggregate amount beneficially owned by each reporting person  

    1,018,464

    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    5.0%

    12. type of reporting person (See Instructions)     IN

     

     
     
     
    CUSIP No. 60471P108 13G Page 5 of 8
    Item 1.  

     

    (a) Name of Issuer: Micromatrix Medical Inc.
         
    (b) Address of Issuer’s Principal

    10399 West 70th Street

      Executive Offices:

    Eden Prairie, MN 55344

     

    Item 2.

    (a) Name of Person Filing:

    Neil Gagnon has sole voting and dispositive power over 65,711 shares of the Issuer’s common stock, par value $0.00001 per share (the “Common Stock”). In addition, Mr. Gagnon has shared voting power over 915,651 shares of the Issuer’s Common Stock and shared dispositive power over 952,753 shares of Common Stock.

     

    Mr. Gagnon is the managing member and principal owner of Gagnon Securities LLC (“GS”), an investment adviser registered with the U.S. Securities and Exchange Commission (“SEC”) under the Investment Advisers Act of 1940, as amended (the “Advisers Act”), and a registered broker-dealer, in its role as investment manager to several customer accounts, foundations, partnerships and trusts (collectively, the “Accounts”) to which it furnishes investment advice. GS and Mr. Gagnon may be deemed to share voting power with respect to 650,444 shares of Common Stock held in the Accounts and dispositive power with respect to 684,984 shares of the Issuer’s Common Stock held in the Accounts. GS and Mr. Gagnon expressly disclaim beneficial ownership of all securities held in the Accounts.

     

    Mr. Gagnon is also the Chief Executive Officer of Gagnon Advisors, LLC (“Gagnon Advisors”), an investment adviser registered with the SEC under the Advisers Act. Mr. Gagnon and Gagnon Advisors, in its role as investment manager to Gagnon Investment Associates, LLC (“GIA”), a private investment fund, may be deemed to share voting and dispositive power with respect to the 229,802 shares of the Issuer’s Common Stock held by GIA. Gagnon Advisors and Mr. Gagnon expressly disclaim beneficial ownership of all securities held by GIA.

     

    (b) Address of Principal Business Office 1370 Ave. of the Americas, 24th Floor
      or, if none, Residence: New York, NY 10019

     

    (c) Citizenship:

    Gagnon Securities LLC

    Delaware limited liability company

       

    Gagnon Advisors, LLC

    Delaware limited liability company

       

    Neil Gagnon

    USA

         
    (d) Title of Class of Securities:

    Common Stock, $0.00001 per share

         
    (e) CUSIP Number: 60471P108

     

     
     
     
    CUSIP No. 60471P108 13G Page 6 of 8
       
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)  o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b)  o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c)  o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d)  o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
         
    (e)  o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f)  o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g)  o A parent holding company or control person in accordance with § 13d-1(b)(1)(ii)(G);
         
    (h)  o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i)  o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15U.S.C. 80a-3);
         
    (j)  o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k)  o Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

     
     
     
    CUSIP No. 60471P108 13G Page 7 of 8
    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:

    Gagnon Securities LLC

    684,984

         

    Gagnon Advisors, LLC

    229,802

         

    Neil Gagnon

    1,018,464

           
      (b) Percent of class:

    Gagnon Securities LLC

    3.4%

         

    Gagnon Advisors, LLC

    1.1%

         

    Neil Gagnon

    5.0%

           
         

    Calculation of percentage of beneficial ownership is based on 20,254,645 shares of Common Stock outstanding as of November 11, 2021 as disclosed in the issuer’s quarterly report on Form 10-Q dated November 15, 2021.

           
      (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote:

    Gagnon Securities LLC

    0

         

    Gagnon Advisors, LLC

    0
         

    Neil Gagnon

    65,711

           
      (ii) Shared power to vote or to direct the vote:

    Gagnon Securities LLC

    650,444

         

    Gagnon Advisors, LLC

    229,802

         

    Neil Gagnon

    915,651

           
      (iii) Sole power to dispose or to direct the disposition of:

    Gagnon Securities LLC

    0
         

    Gagnon Advisors, LLC

    0
         

    Neil Gagnon

    65,711

           
      (iv) Shared power to dispose or to direct the disposition of:

    Gagnon Securities LLC

    684,984

         

    Gagnon Advisors, LLC

    229,802

         

    Neil Gagnon

    952,753

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    The Accounts described above in Item 2 have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, securities held in their respective accounts. To the knowledge of the Reporting Persons the interest in any such account does not exceed 5% of the class of securities. Except to the extent described herein, the Reporting Person disclaims beneficial ownership of all such securities.

     

    Items 7 – 9. Not Applicable.

     

     
     
     
    CUSIP No. 60471P108 13G Page 8 of 8
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 230.14a-11.

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 16, 2022

       
      NEIL GAGNON
       
     

    /s/ Neil Gagnon

       
     

    GAGNON SECURITIES LLC

       
     

    /s/ Neil Gagnon

      Name:  Neil Gagnon 
     

    Title:    Managing Member

       
     

    GAGNON ADVISORS, LLC

       
     

    /s/ Neil Gagnon

      Name:  Neil Gagnon 
     

    Title:    Chief Executive Officer

       
     
     
    Get the next $MIRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MIRO

    DatePrice TargetRatingAnalyst
    7/19/2021$22.00Buy
    Craig Hallum
    More analyst ratings

    $MIRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger

      United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on Decem

      12/13/23 9:15:00 AM ET
      $MIRO
      $UTHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • United Therapeutics and Miromatrix Medical Announce Successful Tender Offer

      United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. ("Merger Sub"), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on December 11, 2023. Contine

      12/12/23 6:00:00 AM ET
      $MIRO
      $UTHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Miromatrix Reports Third Quarter 2023 Results

      EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to

      11/14/23 4:05:00 PM ET
      $MIRO
      $UTHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MIRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Miromatrix Medical with a new price target

      Craig Hallum initiated coverage of Miromatrix Medical with a rating of Buy and set a new price target of $22.00

      7/19/21 8:16:42 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider United Therapeutics Corp claimed ownership of 27,419,228 shares (SEC Form 3)

      3 - Miromatrix Medical Inc. (0001527096) (Issuer)

      12/14/23 2:06:09 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Heine Lisa Wipperman returned 67,413 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Miromatrix Medical Inc. (0001527096) (Issuer)

      12/13/23 4:51:18 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Maag Peter returned 58,368 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Miromatrix Medical Inc. (0001527096) (Issuer)

      12/13/23 4:50:50 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Leadership Updates

    Live Leadership Updates

    See more
    • ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

      DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i

      1/9/23 6:00:00 AM ET
      $AXGN
      $MIRO
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Miromatrix Appoints Jack Lake, M.D., as Medical Director

      EDEN PRAIRIE, Minn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced today that it has appointed Jack Lake, M.D. as the Company's new Medical Director. Dr. Lake is a Professor of Surgery and Medicine and the Chief of Hepatology in the Department of Medicine at the University of Minnesota. He is also the Executive Medical Director for Solid Organ Transplantation at the University of Minnesota Medical Center. Dr. Lake will serve as Miromatrix's Medical Director while remaining in his current roles at the Universit

      8/10/22 7:00:00 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Miromatrix Names Jim Douglas as New Chief Financial Officer

      EDEN PRAIRIE, Minn., March 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced the appointment of Jim Douglas as the Company's new Chief Financial Officer (CFO) effective March 1, 2022. As CFO, Jim will lead Miromatrix's finance organization and oversee all financial activities of the corporation. Mr. Douglas will succeed Brian Niebur, who will continue to serve Miromatrix as the Vice President of Finance. "On behalf of everyone at Miromatrix and our Board of Directors, I want to thank Brian for his many contributions duri

      3/1/22 5:15:00 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Miromatrix Medical Inc. (Amendment)

      SC 13G/A - Miromatrix Medical Inc. (0001527096) (Subject)

      2/14/24 5:00:01 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Miromatrix Medical Inc. (Amendment)

      SC 13G/A - Miromatrix Medical Inc. (0001527096) (Subject)

      2/14/24 1:59:27 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Miromatrix Medical Inc.

      SC 13D - Miromatrix Medical Inc. (0001527096) (Subject)

      12/22/23 9:51:15 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Financials

    Live finance-specific insights

    See more
    • Miromatrix Reports Third Quarter 2023 Results

      EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to

      11/14/23 4:05:00 PM ET
      $MIRO
      $UTHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update

      EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update. "Miromatrix remains on pace to submit a response to the FDA's clinical hold letter relating to our miroliverELAPtm IND application in the second half of 2023," said Jeff Ross, Ph.D., Miromatrix CEO. "We continue to progress towards our goal of gaining authorization from the FDA to initiate a Phase 1 clinical trial to treat patients suffering from acute liver failure and

      8/14/23 4:01:00 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Miromatrix to Report Second Quarter 2023 Financial Results

      EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the second quarter 2023 after market close on Monday, August 14, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 866-652-5200 for domestic callers or 412-317-6060 for international callers. Please reference Conference ID: 10181369. To l

      7/25/23 4:01:00 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Miromatrix Medical Inc.

      15-12G - Miromatrix Medical Inc. (0001527096) (Filer)

      12/26/23 6:02:20 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Miromatrix Medical Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update

      8-K - Miromatrix Medical Inc. (0001527096) (Filer)

      12/18/23 4:30:50 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Miromatrix Medical Inc.

      EFFECT - Miromatrix Medical Inc. (0001527096) (Filer)

      12/18/23 12:15:26 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care